Printer Friendly

QUIDEL OFFERS SYNOPSIS OF REMARKS AT CRUTTENDEN SOUTHERN CALIFORNIA GROWTH STOCK CONFERENCE

 NEWPORT BEACH, Calif., Feb. 17 /PRNewswire/ -- The following is a summary of a presentation made by Newport Beach-based Quidel Corp.'s (NASDAQ: QDEL) Scott L. Glenn, chairman and chief executive officer, today at the Cruttenden Southern California Growth Stock Conference.
 Founded in 1979, Quidel develops, manufactures, and markets rapid immunodiagnostic products that provide simple, accurate and cost- effective diagnoses in the areas of human fertility, infectious diseases, allergies, and autoimmune disorders. These state-of-the- art tests are designed for use at point-of-care sites; the physician's office, clinical laboratory, and home testing markets. Quidel is a leading provider of rapid immunodiagnostic tests for these markets.
 The rapid testing market has grown to approximately $1 billion, fueled by the demand for more accurate and easier-to-use immunoassays and the public's increased awareness of the need to control health care costs. Quidel's focus is to blend innovative biotechnology, immunochemistry and engineering into innovative new products for family planning and family care that are both sophisticated and easy- to-use, providing early diagnosis of disease states and other medical conditions.
 Fertility products: Quidel manufactures a broad line of tests for fertility specialists and Ob/Gyn physicians. Products predict ovulation and confirm pregnancy in women. The company also markets a line of home testing fertility products under the Conceive(TM) brand name. These tests are one-step urine assays. New products include a test to confirm ovulation occurred, and a novel birth control diagnostic which will help 50 million women who are presently practicing natural family planning and barrier birth control determine when it is safe to have intercourse without becoming pregnant.
 Infectious disease products: Quidel manufactures the No. 1 selling strep throat test in the doctor's office for its partner, Becton Dickinson. The company was also first to introduce a rapid test for Helicobacter pylori, the bacteria known to cause about 85 percent of peptic ulcers. The good news is that ulcers caused by this bacteria are now curable. Quidel is uniquely poised to capture a major share of this developing market with the only Food and Drug Administration-approved rapid test for the detection of H. pylori. The company has also led the way in developing a rapid test for Group B Streptococcus, which is the No. 1 life threatening infection to newborns.
 Allergy products: Quidel continues to improve its competitive position through the development of several new rapid allergy screens designed for doctor's office testing in the United States and in the expanding European markets. The company has under development a line of rapid one-step allergy tests that reduce test times from hours to minutes from a simple finger prick blood sample with specific aim at the self-testing/pharmacy market.
 Quidel also announced today under a separate news release that it has filed with the U.S. Food and Drug Administration (FDA) for clearance to market its new rapid immunoassay called QuickVue(TM) One-Step Fecal Occult Blood Test. This is a two-minute doctor's office product that detects hidden blood in feces and is considered an important first step in the early detection of many gastrointestinal disorders, including colorectal cancer. This new test circumvents the dietary restrictions imposed by traditional tests. The American Cancer Society recommends that all asymptomatic, low-risk patients over the age of 40 years be routinely tested for fecal occult blood as part of their annual physical examination. Colorectal cancer is one of the most deadly forms of cancer and is second only to lung cancer.
 -0- 2/17/93
 /CONTACT: Scott L. Glenn, chairman and CEO, 619-552-7900, or Mark Francois, manager, investor relations, 619-552-7931, both of Quidel Corp./
 (QDEL)


CO: Quidel Corp. ST: California IN: MTC SU:

MS-LS -- LA001 -- 7146 02/17/93 08:48 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 17, 1993
Words:612
Previous Article:TEAMSTERS PRESIDENT PLEDGES SOLIDARITY WITH STRIKING COAL MINERS
Next Article:LESLIE'S POOLMART OFFERS SYNOPSIS OF REMARKS AT CRUTTENDEN SOUTHERN CALIFORNIA GROWTH STOCK CONFERENCE
Topics:


Related Articles
QUIDEL AND JOHN HANCOCK CONVERT QUIDEL DEBT TO EQUITY
QUIDEL AND AMOCO CONVERT QUIDEL DEBT TO EQUITY
SOUTHERN CALIFORNIA GROWTH STOCK CONFERENCE PRESENTATION SUMMARY: I-FLOW
QUIDEL ANNOUNCES MANAGEMENT TRANSITION
I-FLOW CORP. OFFERS SYNOPSIS OF REMARKS AT CRUTTENDEN SOUTHERN CALIFORNIA GROWTH STOCK CONFERENCE
I-FLOW CORPORATION EXPANDS FAMILY OF SYRINGE PUMPS
QUIDEL TO PRESENT AT VAN KASPER GROWTH STOCK CONFERENCE
HEALTHCARE FIRMS CONVERGE ON BIG APPLE; CRUTTENDEN ROTH CONFERENCE BEGINS TOMORROW
QUIDEL Corporation Implements Stockholder Rights Plan
QUIDEL Receives $5 Million from the Exercise of Expiring Warrants

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters